If you enjoy this content, please share it with a colleague
RELATED CONTENT
A 2013 survey of radiation oncologists indicates that they would like more formal recommendations and guidance in order to improve the peer review process, according to a study published in the January-February 2015 issue of Practical Radiation Oncology (PRO), the clinical practice journal of the American Society for Radiation Oncology (ASTRO).
A new study on the use of hypofractionated whole-breast irradiation (HF-WBI) for early-stage breast cancer patients found HF-WBI increased 17.4 percent from 2004 to 2011. Patients are also more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ?50 miles away from a cancer center. The study was published in the Dec. 1, 2014, issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term local control on 79 percent of tumors for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012. The research was presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.
The American Society for Radiation Oncology (ASTRO) is supporting the Centers for Medicare and Medicaid Services' (CMS) decision to provide coverage for annual lung cancer screening via a low-dose CT screening for those at the highest-risk for lung cancer.
Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine.
September 16, 2014 — A large, international analysis of patients with stage IV non-small cell lung cancer (NSCLC) indicates that a patient’s overall survival (OS) rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for “low-risk” patients leads to a five-year OS rate of 47.8 percent. The research was presented today at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO).
Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy (SBRT) have a five-year survival rate of 40 percent, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.
A prospective clinical study that compared patient-reported outcomes of a broad set of cancer patients with bone metastases demonstrates that single fraction radiation therapy (SFRT) is equally as effective as multiple fraction radiation therapy (MFRT) when pain, function and quality of life are considered, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.
Mobility is equally preserved in cancer patients suffering from malignant spinal cord compression (MSCC) who receive a single dose of 10 Gy of radiation therapy (RT), compared to patients who receive five daily doses of 4 Gy of RT each, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.
Prostate cancer patients who received hypofractionated (HPFX) radiation therapy (RT) reported that their quality of life, as well as bladder and bowel function, were at similar levels before and after RT, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.